170 related articles for article (PubMed ID: 36817141)
1. 14-day pantoprazole- and amoxicillin-containing high-dose dual therapy for
Yang Q; He C; Hu Y; Hong J; Zhu Z; Xie Y; Shu X; Lu N; Zhu Y
Front Pharmacol; 2023; 14():1096103. PubMed ID: 36817141
[No Abstract] [Full Text] [Related]
2. Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomized-controlled trial.
Shao QQ; Yu XC; Yu M; Ma J; Zhao JB; Yuan L; Qi YB; Hu RB; Wei PR; Xiao W; Lan L; Jia BL; Zhang LZ; Ding SZ
Helicobacter; 2022 Apr; 27(2):e12876. PubMed ID: 35150597
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of high-dose ilaprazole-amoxicillin dual therapy for
Cheng J; Fan C; Huang K; Zhai L; Wang H; Xie D; Cai Y; Li Z; Bai Q; Wang P; Ding H
Front Pharmacol; 2023; 14():1272744. PubMed ID: 38026958
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of high-dose esomeprazole and amoxicillin dual therapy
Mei H; Guo Y; Zhao JT; Yang J; Sun WJ; Zhang DK; He P; Shi G; Su NY; Han R; Lan CH
Therap Adv Gastroenterol; 2022; 15():17562848221142925. PubMed ID: 36600686
[TBL] [Abstract][Full Text] [Related]
5. Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
Tian XL; Suo BJ; Zhang H; Lu HP; Li CL; Zhang YX; Ren XL; Yao XY; Zhou LY; Song ZQ
Helicobacter; 2023 Feb; 28(1):e12935. PubMed ID: 36374159
[TBL] [Abstract][Full Text] [Related]
6. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial.
Macías-García F; Bastón-Rey I; de la Iglesia-García D; Calviño-Suárez C; Nieto-García L; Domínguez-Muñoz JE
Helicobacter; 2019 Feb; 24(1):e12546. PubMed ID: 30346636
[TBL] [Abstract][Full Text] [Related]
7. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of vonoprazan-amoxicillin dual therapy for
Wang X; Teng G; Dong X; Dai Y; Wang W
Therap Adv Gastroenterol; 2023; 16():17562848231190976. PubMed ID: 37664169
[TBL] [Abstract][Full Text] [Related]
9. Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: An open-label, multicenter, randomized controlled trial.
Guan JL; Hu YL; An P; He Q; Long H; Zhou L; Chen ZF; Xiong JG; Wu SS; Ding XW; Luo HS; Li PY
Pharmacotherapy; 2022 Mar; 42(3):224-232. PubMed ID: 35075679
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial.
Bi H; Chen X; Chen Y; Zhao X; Wang S; Wang J; Lyu T; Han S; Lin T; Li M; Yuan D; Liu J; Shi Y
Chin Med J (Engl); 2022 Jul; 135(14):1707-1715. PubMed ID: 36193978
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of bismuth quadruple therapy, sequential therapy, and hybrid therapy as a first-line regimen for
Koroglu M; Ayvaz MA; Ozturk MA
Niger J Clin Pract; 2022 Sep; 25(9):1535-1541. PubMed ID: 36149216
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
[TBL] [Abstract][Full Text] [Related]
13. Impact of insufficient doses of medications on
Shi X; Wang C; Meng F; Ma S; Xu G; Liu T; Guo X; Li H; Qi X
Postgrad Med; 2022 Sep; 134(7):668-674. PubMed ID: 35860966
[TBL] [Abstract][Full Text] [Related]
14. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial.
Tai WC; Liang CM; Kuo CM; Huang PY; Wu CK; Yang SC; Kuo YH; Lin MT; Lee CH; Hsu CN; Wu KL; Hu TH; Chuah SK
J Antimicrob Chemother; 2019 Jun; 74(6):1718-1724. PubMed ID: 30768161
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial.
Song Z; Zhou L; Xue Y; Suo B; Tian X; Niu Z
Helicobacter; 2020 Dec; 25(6):e12762. PubMed ID: 33040439
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial comparing seven-day ranitidine bismuth citrate and clarithromycin dual therapy to seven-day omeprazole, clarithromycin and amoxicillin triple therapy for the eradication of Helicobacter pylori.
Veldhuyzen van Zanten S; Chiba N; Barkun A; Fallone C; Farley A; Cockeram A; Dallaire C; Simms L; Nicholls B
Can J Gastroenterol; 2003 Sep; 17(9):533-8. PubMed ID: 14532926
[TBL] [Abstract][Full Text] [Related]
17. The prospective multiple-centre randomized controlled clinical study of high-dose amoxicillin-proton pump inhibitor dual therapy for
Shen C; Li C; Lv M; Dai X; Gao C; Li L; Zhang Q; Pan W; Liu C; Han S; Zhang Y; Ding S; Deng H; Yao Y; Xu J; Wei M; Shi H; Yuan P; Yang X; Jian Y; Shan J; Liu Y; Chen Z; Deng X; Liu F; Deng L; Zhong X; Li H; He S; Chen L; Liu G; Xu H; Zhong Y; Shi H; Ren J;
Ann Med; 2022 Dec; 54(1):426-435. PubMed ID: 35098820
[TBL] [Abstract][Full Text] [Related]
18. Non-Bismuth Quadruple Therapy, Sequential Therapy or High-Dose Esomeprazole and Amoxicillin Dual Therapy for First-Line Helicobacter pylori Eradication: A Prospective Randomized Study.
Zeriouh M; Elmekkaoui A; Bouqfar M; Zazour A; Khannoussi W; Kharrasse G; Abda N; Ismaili Z
Cureus; 2020 Dec; 12(12):e11837. PubMed ID: 33409077
[TBL] [Abstract][Full Text] [Related]
19. Modified bismuth quadruple therapy with low-dose metronidazole as first-line therapy for Helicobacter pylori infection.
Pih GY; Choi KD; Gong EJ; Na HK; Ahn JY; Lee JH; Jung KW; Kim DH; Song HJ; Lee GH; Jung HY
Helicobacter; 2021 Feb; 26(1):e12759. PubMed ID: 33113240
[TBL] [Abstract][Full Text] [Related]
20. Modified quadruple therapy or bismuth-containing quadruple therapy in the first-line treatment of Helicobacter pylori in Turkey.
Yozgat A; Kasapoğlu B; Demirci S; Coşkun Sökmen F
Rev Esp Enferm Dig; 2021 Jul; 113(7):490-493. PubMed ID: 33233910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
